Overview

A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

Status:
Terminated

Trial end date:
2020-08-11

Target enrollment:

Participant gender:

Summary

The reason for this study is to compare the efficacy of abemaciclib, in combination with fulvestrant, to that of physician's choice of chemotherapy in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer that has spread to internal organs. Your participation in this trial could last up to 31 months, depending on your cancer type and how you and your tumor respond.

Phase:

Phase 4

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Albumin-Bound Paclitaxel
Capecitabine
Docetaxel
Fulvestrant
Paclitaxel